Market revenue in 2023 | USD 411.6 million |
Market revenue in 2030 | USD 1,010.1 million |
Growth rate | 13.7% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 31.24% in 2023. Horizon Databook has segmented the Brazil upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil’s biopharmaceutical industry has grown steadily in recent years, with continuous innovation and expansion of biopharmaceuticals. In September 2019, Samsung Bioepis, a South Korean company, partnered with Brazil’s Ministry of Health to supply a biotherapeutic product, Brenzys, for the treatment of rheumatoid arthritis in Brazil for the next 10 years.
This further raises awareness about biopharmaceuticals in Brazil, accelerating their development and consequently boosting upstream bioprocesses. Government agencies, universities, and institutes are promoting biologic development in Brazil. According to data by BioWorld, around 61% of Brazil’s total annual spending is on biologics.
As per Generics and Biosimilars Initiative, the Ministry of Health aims to save as much as USD 225 million every year by encouraging pharmaceutical companies to develop biosimilars for the Brazilian market. Such efforts are expected to drive bioprocessing procedures involved in the development of biologics.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil upstream bioprocessing market , including forecasts for subscribers. This country databook contains high-level insights into Brazil upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account